Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma

Summary. Malignant plasma cells generally grow within the bone marrow microenvironment; however, they can also grow at extramedullary sites. To identify the tumour‐specific alterations required for extramedullary growth, we analysed the expression profiles of a series of plasma cell neoplasms including primary multiple myeloma (MM), plasma cell leukaemia (PCL) and extramedullary plasmacytoma (EPC). Hierarchical clustering analysis segregated the EPCs from the remaining samples, and revealed an expression pattern associated with angiogenesis in the EPCs, involving higher expression of the genes TIE2, NOTCH3, CD31 and endoglin. Direct comparison of EPC samples with the MM samples identified 156 genes significantly upregulated and 85 genes significantly downregulated (P < 0·005, t‐test) in the EPCs, including several genes involved in angiogenesis and adhesion that were upregulated (including angiopoietin 1, SPARC, Notch3 and fibronectin 1). Immunohistochemical staining demonstrated CD31 and endoglin protein expression in the EPC tumour cells, which are both angiogenesis related and could confer malignant plasma cells with the ability to grow outside the normal bone marrow environment. Defining how malignant plasma cell growth is regulated in the bone marrow versus at extramedullary sites will help to delineate the mechanisms underlying the dependence of tumour cell growth on angiogenesis and cell adhesion.

[1]  W. Berdel,et al.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. , 2000, Blood.

[2]  M. Potter,et al.  Induction of Plasma Cell Tumours in BALB/c Mice with 2,6,10,14-Tetramethylpentadecane (Pristane) , 1969, Nature.

[3]  D. Leroith,et al.  Insulin-like Growth Factors and Cancer , 1995, Annals of Internal Medicine.

[4]  R. Bataille,et al.  Interleukin-6 is a growth factor for nonmalignant human plasmablasts. , 2001, Blood.

[5]  R. Timpl,et al.  Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules. , 1998, Cell adhesion and communication.

[6]  M. Albitar Angiogenesis in Acute Myeloid Leukemia and Myelodysplastic Syndrome , 2002, Acta Haematologica.

[7]  H. Zhang,et al.  Endoglin is a component of the transforming growth factor (TGF)-beta receptor complex of human pre-B leukemic cells. , 1996, Journal of immunology.

[8]  K. Anderson,et al.  Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays , 2002, Oncogene.

[9]  S. Rudikoff,et al.  Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. , 2000, Blood.

[10]  W. Bellamy Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. , 2001, Seminars in oncology.

[11]  P. L. Bergsagel,et al.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Cheng Li,et al.  Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application , 2001, Genome Biology.

[13]  J. V. van Mourik,et al.  Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. , 1992, International immunology.

[14]  J. Miyazaki,et al.  Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  B. Klein,et al.  Interleukin-6 in human multiple myeloma. , 1995, Blood.

[16]  Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma , 2001, European journal of haematology.

[17]  G. Gray,et al.  Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. , 1990, Science.

[18]  G. Pinkus,et al.  The development of a model for the homing of multiple myeloma cells to human bone marrow. , 1997, Blood.

[19]  K. Anderson,et al.  Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. , 2001, Blood.

[20]  T. Rasmussen,et al.  Differential expression of CD56 and CD44 in the evolution 
of extramedullary myeloma , 2002, British journal of haematology.

[21]  C. Duan Specifying the cellular responses to IGF signals: roles of IGF-binding proteins. , 2002, The Journal of endocrinology.

[22]  N. Kay,et al.  B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules , 2002, Leukemia.

[23]  D. Govender,et al.  CD31 (JC70) expression in plasma cells: an immunohistochemical analysis of reactive and neoplastic plasma cells. , 1997, Journal of clinical pathology.

[24]  O. Podhajcer,et al.  Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells , 1997, Nature Medicine.

[25]  D. Ribatti,et al.  Bone Marrow Angiogenesis and Plasma Cell Angiogenic and Invasive Potential in Patients with Active Multiple Myeloma , 2002, Acta Haematologica.

[26]  Masato Nakamura,et al.  Angiopoietin-1 and vascular endothelial growth factor expression in human esophageal cancer. , 2002, International journal of molecular medicine.

[27]  S. Tura,et al.  Antiangiogenic Therapy in Multiple Myeloma , 2001, Acta Haematologica.

[28]  H. F. Barker,et al.  The role of adhesion molecules in multiple myeloma. , 1997, Leukemia & lymphoma.

[29]  A. Hidalgo,et al.  Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. , 2001, Blood.

[30]  D. Ribatti,et al.  Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA‐1, VLA‐4, LAM‐1, and CD44 , 1995, American journal of hematology.

[31]  J. Norton,et al.  Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. , 2001, Blood.

[32]  J. Berenson Advances in the biology and treatment of myeloma bone disease. , 2002, Seminars in oncology.

[33]  S. Bauer,et al.  Increased expression of myc-related oncogene mRNA characterizes most BALB/c plasmacytomas induced by pristane or Abelson murine leukemia virus. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Grogan,et al.  Long-term engraftment of fresh human myeloma cells in SCID mice. , 1992, Blood.

[35]  R. Strieter,et al.  Interleukin-8 as a macrophage-derived mediator of angiogenesis. , 1992, Science.

[36]  W. Dalton,et al.  The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance , 2000, Current opinion in oncology.

[37]  K. Calame,et al.  Plasma cells: finding new light at the end of B cell development , 2001, Nature Immunology.

[38]  D. Clemmons,et al.  Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Chilosi,et al.  Human myeloma cells express the CD38 ligand CD31 , 1999, British journal of haematology.

[40]  H. Namba,et al.  Tie-2 and angiopoietin-1 expression in human thyroid tumors. , 2002, Thyroid : official journal of the American Thyroid Association.

[41]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[42]  A. Feller,et al.  Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia. , 2002, Leukemia research.

[43]  A. Falus,et al.  Mouse plasmacytoma: an experimental model of human multiple myeloma. , 2001, Haematologica.

[44]  J. D. Vos,et al.  Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays , 2002, Oncogene.

[45]  J. Woodgett,et al.  A molecular compendium of genes expressed in multiple myeloma. , 2002, Blood.

[46]  JS Damiano,et al.  Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and γ-irradiation , 2001, Leukemia.

[47]  P. L. Bergsagel,et al.  Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.

[48]  H. Schuurman,et al.  The SCID mouse as a model for multiple myeloma , 1995, British journal of haematology.

[49]  John Crowley,et al.  Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. , 2002, Blood.

[50]  R. Bataille,et al.  Mcl‐1 and Bcl‐xL are co‐regulated by IL‐6 in human myeloma cells , 1999, British journal of haematology.

[51]  D Puthier,et al.  High incidence of N and K‐Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis , 2001, Human mutation.

[52]  V. Cheng,et al.  Extramedullary Plasmacytoma of the Head and Neck: A CLINICOPATHOLOGIC STUDY OF 20 CASES , 1982, Medicine.

[53]  John Calvin Reed,et al.  BCL-X expression in multiple myeloma: possible indicator of chemoresistance. , 1998, Cancer research.

[54]  D. Ribatti,et al.  Bone marrow angiogenesis in patients with active multiple myeloma. , 2001, Seminars in oncology.